FDA Approval Alert: The Need-to-Know | Dato-DXd in Pretreated EGFR-Mutated Metastatic NSCLC
In June 2025, the FDA granted accelerated approval to datopotamab deruxtecan (dato-DXd) as a treatment for patients with pretreated EGFR-mutant metastatic non–small cell lung cancer.